New hope for rare lung and liver disease: experimental drug WVE-006 enters human testing

NCT ID NCT06405633

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tests an experimental drug called WVE-006 in 24 adults with a genetic condition called alpha-1 antitrypsin deficiency (AATD), which can damage the lungs and liver. The goal is to see if the drug is safe and how it moves through the body. Participants receive either a single dose or multiple doses of the drug, and researchers monitor side effects and changes in blood protein levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cambridge University - Addenbrooke's Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Dalhousie University - Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Inspiration Research Limited

    Toronto, Ontario, M5T 3A9, Canada

  • Queen Elizabeth Hospital, University Hospital Birmingham

    Birmingham, B15 2GW, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, SW8 3RN, United Kingdom

  • St. Vincent's Hospital, Melbourne

    Fitzroy, Victoria, 3065, Australia

  • Turku University Hospital

    Turku, 20520, Finland

  • Universitaetsklinikum Aachen, AoeR

    Aachen, 52074, Germany

  • Waikato Hospital

    Hamilton, 3204, New Zealand

Conditions

Explore the condition pages connected to this study.